DAX25.004 -0,6%Est506.265 -0,2%MSCI World4.343 -0,1%Top 10 Crypto8,4100 +1,3%Nas26.213 +0,4%Bitcoin57.057 +0,3%Euro1,1435 +0,1%Öl83,54 -1,4%Gold4.048 -0,2%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 SpaceX A42D4F NVIDIA 918422 IBM 851399 PayPal A14R7U SAP 716460 Infineon 623100 Siemens Energy ENER6Y Deutsche Telekom 555750 Volkswagen (VW) vz. 766403 Micron Technology 869020 EVOTEC 566480 Microsoft 870747 BYD A0M4W9 Lufthansa 823212
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX ringt um 25.000-Punkte-Marke -- Wall Street freundlich -- ASML hebt Umsatzziel an -- PayPal erhält Übernahmeangebot -- Nebius, SpaceX, IBM, XPeng, Microsoft, BASF, Intel, NEL, Rheinmetall im Fokus
Top News
Kryptowährungen: Aktueller Marktbericht zu Bitcoin & Co. Kryptowährungen: Aktueller Marktbericht zu Bitcoin & Co.
Bären übernehmen: DAX gibt nach - 25.000er-Marke bleibt umkämpft - Blick richtet sich auf Berichtssaison Bären übernehmen: DAX gibt nach - 25.000er-Marke bleibt umkämpft - Blick richtet sich auf Berichtssaison
Suche...
Jetzt kostenlos
bei finanzen.net anmelden
Watchlists & Musterdepots Tools & integriertes Trading Newsletter, Trading-Desk uvm.
Schon einen Account? Anmelden
Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Novo Nordisk (spons. ADRs) Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
44,42 EUR +1,44 EUR +3,35 %
STU
50,77 USD +1,70 USD +3,46 %
BTT
finanzen.net zero
Novo Nordisk (spons. ADRs) jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone
KGV14,59Div. Rendite2,53%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN866931

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS6701002056

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolNVO

Novo Nordisk (spons. ADRs) Aktien News

DatumMeistgelesen
PR NewswireNovo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America
PR NewswireNovo Nordisk's CagriSema was associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart dise...
PR NewswireNovo Nordisk's CagriSema was associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart dise...
Wer­bungNovo Nordisk (spons. ADRs)-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR Newswire/C O R R E C T I O N -- Metsera, Inc./
PR NewswireMetsera Receives Amended Proposal from Novo Nordisk; Metsera Declares Novo Nordisk Amended Proposal "Superior"
PR NewswireMetsera Receives Unsolicited Proposal from Novo Nordisk
PR NewswireNVO Deadline: NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit
PR NewswireCLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Novo Nordisk A/S (NYSE: NVO) Investors to Inquire About a Securities Fraud Class Action by September 30, 2025
PR NewswireSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO
PR NewswireDEADLINE APPROACHING: Berger Montague Advises Nordisk A/S (NYSE: NVO) Investors to Inquire About a Securities Fraud Class Action by September 30, 2025
PR NewswireNovo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before September 30, 2025 to Discuss Your Rights - NVO
PR NewswireNVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit with the Schall Law Firm
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO
PR NewswireNOVO NORDISK A/S (NYSE: NVO) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action by September 30, 2025
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO
PR NewswireLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 30, 2025 in Novo Nordisk A/S Lawsuit - NVO
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO
PR NewswireNovo Nordisk A/S Sued for Securities Law Violations - Contact Levi & Korsinsky Before September 30, 2025 to Discuss Your Rights - NVO
PR NewswireNYSE: NVO DEADLINE REMINDER: Berger Montague Reminds Nordisk A/S (NYSE: NVO) Investors of Important Class Action Lawsuit Deadline
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO
PR NewswireNVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit with the Schall Law Firm
PR NewswireNovo Nordisk A/S Sued for Securities Law Violations - Contact The Gross Law Firm Before September 30, 2025 to Discuss Your Rights - NVO
PR NewswireINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO
PR NewswireNVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit with the Schall Law Firm
PR NewswireNVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO
PR NewswireSHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
PR NewswireINVESTOR REMINDER: Berger Montague Notifies Novo Nordisk A/S (NYSE: NVO) Investors of a Class Action Lawsuit and Deadline
PR NewswireNVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit with the Schall Law Firm
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO
PR NewswireWegovy® approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis
PR NewswireFaruqi & Faruqi Reminds Novo Nordisk Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 30, 2025 - NVO
PR NewswireNVO LAWSUIT ALERT: The Gross Law Firm Notifies Novo Nordisk A/S Investors of a Class Action Lawsuit and Upcoming Deadline
PR NewswireNovo Nordisk A/S (NVO) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
PR NewswireNVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit with the Schall Law Firm
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO
PR NewswireNVO Investors are Reminded of Final Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit with the Schall Law Firm
PR NewswireNVO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Novo Nordisk (spons. ADRs) News

Novo Nordisk (spons. ADRs) News: auf dieser Seite finden Sie alle Novo Nordisk (spons. ADRs) News und Nachrichten zur Novo Nordisk (spons. ADRs) Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Novo Nordisk (spons. ADRs) News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Novo Nordisk (spons. ADRs) News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.